Orpheus Uranium Raises $4.36M with IsoEnergy as Cornerstone Investor

Strategic Capital Raise Bolsters Exploration Ambitions

Orpheus Uranium Limited (ASX, ORP) has successfully secured firm commitments to raise $4.36 million through a share placement priced at 6.2 cents per share. The raise, announced on 4 February 2026, will see the issue of approximately 70.4 million new shares, providing the company with fresh capital to push forward its uranium exploration projects across South Australia, the Northern Territory, and Western Australia.

The placement was led by IsoEnergy Ltd., a globally diversified uranium company with a market capitalisation near $1 billion AUD. IsoEnergy’s $1.5 million cornerstone investment not only injects significant funds but also signals strong confidence in Orpheus’ portfolio and management team. IsoEnergy’s involvement is particularly noteworthy given its established reputation in the uranium sector and its strategic alignment with Orpheus’ growth plans.

Funding Focus and Market Context

The proceeds from the placement are earmarked for advancing exploration activities at Orpheus’ key projects, including the recently acquired Oobagooma Uranium Project in Western Australia. This diversification across three jurisdictions reflects Orpheus’ strategy to build a robust pipeline of assets at various stages of development, aiming to capitalise on the anticipated rise in uranium prices driven by global energy transition trends.

Orpheus Managing Director Clinton Dubieniecki welcomed IsoEnergy’s participation, highlighting it as a strong endorsement of the company’s technical capabilities and project quality. The placement shares were issued at a 2.9% discount to the 15-day volume weighted average price, a modest concession that balances investor appeal with shareholder value preservation.

Placement Management and Shareholder Considerations

Taylor Collison Limited acted as the sole lead manager for the placement, receiving a 2% fee on total proceeds and additional incentives in the form of unlisted options subject to shareholder approval. These options carry an exercise price set at a 50% premium to the placement price and expire three years from allotment, aligning the manager’s interests with Orpheus’ long-term growth.

The new shares will rank equally with existing shares, ensuring no dilution of shareholder rights beyond the capital increase. The placement is being conducted under the company’s existing capacity, avoiding the need for a general meeting and allowing for swift completion, with settlement and allotment scheduled for early February.

Looking Ahead

With the capital raise complete, Orpheus is positioned to accelerate its exploration programs and further develop its uranium asset base. The partnership with IsoEnergy may also open doors for future collaboration or co-investment opportunities, potentially enhancing Orpheus’ profile in the competitive uranium sector.